Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)

被引：0
|
作者：
Vienne, A. [1 ]
Collet, L. [2 ]
Chevalier, T. [3 ]
Borel, C. [4 ]
Tardy, M. P. [5 ]
Huguet, F. [6 ]
Richard, S. [7 ]
Salas, S. [3 ]
Saada-Bouzid, E. [5 ]
Fayette, J. [2 ]
Daste, A. [1 ]
机构：
[1] CHU Bordeaux Hop St Andre, Gironde, Bordeaux, France
[2] Ctr Leon Berard, Med, Lyon, France
[3] AP HM, Med Oncol, Marseille, France
[4] ICANS Inst Cancerol Strasbourg Europe, Med Oncol Dept, Strasbourg, France
[5] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France
[6] Hop Tenon, Dept Radiat Oncol, Paris, France
[7] Hosp Tenon, AP HP, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
925P
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [21] Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Obara, Grzegorz
    Sun, Jichao
    Loo, Deryk
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Response to salvage chemotherapy with paclitaxel plus /cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
    Gomez, R. G. Herrera
    Saleh, K.
    Auclin, E.
    Vinches, M.
    Gervais, C.
    Espeli, V. G.
    Rothschild, S. I.
    Even, C.
    Cristina, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S592 - S592
  • [23] Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial
    Machiels, J-P.
    de Castro, G., Jr.
    de Souza Viana, L.
    Galiulin, R.
    Tahara, M.
    Nicolau, U. R.
    Le Tourneau, C.
    Okami, K.
    Vladimirov, V.
    Izmailov, A.
    Hoermann, K.
    Licitra, L.
    Haddad, R.
    Cohen, E.
    Dupuis, N.
    Love, J.
    Zografos, E.
    Ehrnrooth, E.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial
    Adkins, Douglas
    Oppelt, Peter John
    Ley, Jessica C.
    Myneni, Praveen Chowdary
    Gogula, Venkata Ramana
    Kanumuri, Satish
    Yadla, Sheshubabu
    Sadu, Venkata
    Kota, Raghava
    Sanagala, Saipavan
    Surapaneni, Mounika
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN): CHANGES IN 1ST-LINE TREATMENT PATTERNS IN EUROPE 2008-2009
    Wilke, H.
    Vermorken, J.
    Merlano, M. C.
    Bourhis, J.
    Mesia, R.
    Guigay, J.
    Keilholz, U.
    Hartmann, M.
    Lefebvre, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 322 - 322
  • [26] Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Ramakrishnan, Karthik
    Mojebi, Ali
    Ayers, Dieter
    Chirovsky, Diana Romana
    Borse, Rebekah
    Keeping, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] REAL WORLD TREATMENT PATTERNS FOR FIRST LINE (1L) RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PATIENTS
    Contente, M.
    Mtibaa, M.
    Hall, J.
    Bailey, H.
    Bailey, A.
    Di Rienzo, P.
    Polanco, C.
    Singh, P.
    VALUE IN HEALTH, 2019, 22 : S108 - S109
  • [28] Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
    Cohen, Ezra E. W.
    Licitra, Lisa F.
    Fayette, Jerome
    Gauler, Thomas Christoph
    Clement, Paul M.
    Jose Grau, Juan
    Maria Del Campo, Jose
    Mailliez, Audrey
    Haddad, Robert I.
    Vermorken, Jan B.
    Tahara, Makoto
    Guigay, Joel
    Geoffrois, Lionnel
    Merlano, Marco C.
    Dupuis, Nicholas F.
    Burtness, Barbara
    Gibson, Neil
    Solca, Flavio
    Ehrnrooth, Eva
    Machiels, Jean-Pascal H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
    Tahara, M.
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Burtness, B.
    De Castro, G., Jr.
    Psyrri, A.
    Brana, I.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia Nin, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Gumuscu, B.
    Lerman, N.
    Soulieres, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S844 - S844
  • [30] PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)
    Tahara, M.
    Cohen, E. E. W.
    Haddad, R. I.
    Fayette, J.
    Licitra, L. F.
    Clement, P. M.
    Vermorken, J. B.
    Gauler, T.
    Cupissol, D.
    Grau, J. J.
    Guigay, J.
    del Campo, J. M.
    Okami, K.
    Takahashi, S.
    Burtness, B.
    Cong, X. J.
    Gibson, N.
    Solca, F.
    Ehrnrooth, E.
    Machiels, J. -P. H.
    ANNALS OF ONCOLOGY, 2015, 26 : 93 - 93
12345